AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$ORKA

Agarwal Arjun sold $926K of ORKA

Agarwal Arjun (Senior Vice President, Finance) sold 10,019 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $92.43 ($91.11–$95.71, $0.93M total) across 5 trades over 2026-09-11 to 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Agarwal Arjun
Published Sep 15, 2026, 11:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 11:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ORKA
Neutral
medium confidence
Mentioned
$ORKA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORKANeutralLow
01

Why it matters

The disclosed sale is a routine 10b5‑1 execution with limited price impact.

02

Market read

Small insider sale; low immediate trading relevance.

03

What to watch

Potential upcoming FDA decision or trial data could amplify the impact of this sale.

Relevance 4/10Novelty 4/10Timing: filed Sep 15 2026

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$ORKANeutralMedium confidence
Context

Senior VP of Finance sold 10,019 shares for $926,010 via a 10b5‑1 plan, reducing his stake to 14,752 shares.

Expected impact

Potential slight dip in ORKA price, likely limited to a few basis points.

Evidence & confidence

A $926K sale by a senior finance officer is a routine 10b5‑1 execution; market typically reacts minimally to sub‑$1M insider sales.

Market effects

Sector

Minimal impact on biotech sector; similar insider sales are common and not sector‑wide drivers.

Regional

No notable regional effect; the filing is U.S. specific.

Global

Negligible on a global scale.

Counterpoint

What could challenge this read

If the insider had insider knowledge of upcoming negative news, the sale could foreshadow a larger move.

Key entities

  • Officer
    Agarwal Arjun

    Senior Vice President, Finance at Oruka Therapeutics.

  • Company
    Oruka Therapeutics, Inc.

    Biotech firm developing therapies for rare diseases.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ORKA insider trading history →

Related articles

OCT 1
$ORKAMedAI 8/10

How Investors Are Reacting To Oruka Therapeutics (ORKA) Positive Psoriasis Trial Results

Oruka Therapeutics (ORKA) reported positive Week 28 data from its EVERLAST-A Phase 2a trial for ORKA-001 in treating moderate-to-severe plaque psoriasis. The drug showed high PASI 90 and PASI 100 response rates, maintained IGA 0/1 responses, and had a safety profile consistent with the IL-23p19 class. The company has no revenue, reported a net loss of $109.688m, and relies on clinical trials and funding. The stock is up sharply over the past year but down 10.2% over the last month.

simplywall.st2 min
SEP 23
$ORKAMedAI 8/10

Why is Oruka Therapeutics stock sliding today?

Oruka Therapeutics' stock fell 2.5% in pre-market trading after releasing positive but expected Week 28 trial data, with 71.4% of patients achieving complete skin clearance. The company's Chief Medical Officer highlighted the potential of ORKA-001. A pre-planned insider sale of 10,000 shares and a cautious market backdrop also contributed to the decline. Oruka's Price-to-Sales ratio remains high, reflecting growth expectations. The company plans to share more data in December 2026 and Q4 2026.

investing.com2 min